Cyclacel Pharmaceuticals (FRA:UXI) 3-Year Book Growth Rate : -80.70% (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Cyclacel Pharmaceuticals 3-Year Book Growth Rate?

Cyclacel Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2024 was €-1.54.

During the past 12 months, Cyclacel Pharmaceuticals's average Book Value per Share Growth Rate was -109.60% per year. During the past 3 years, the average Book Value per Share Growth Rate was -80.70% per year. During the past 5 years, the average Book Value per Share Growth Rate was -67.20% per year. During the past 10 years, the average Book Value per Share Growth Rate was -52.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Cyclacel Pharmaceuticals was 69.40% per year. The lowest was -80.70% per year. And the median was -42.25% per year.

Competitive Comparison of Cyclacel Pharmaceuticals's 3-Year Book Growth Rate

For the Biotechnology subindustry, Cyclacel Pharmaceuticals's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyclacel Pharmaceuticals's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyclacel Pharmaceuticals's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Cyclacel Pharmaceuticals's 3-Year Book Growth Rate falls into.

Cyclacel Pharmaceuticals 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Cyclacel Pharmaceuticals (FRA:UXI) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Cyclacel Pharmaceuticals 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Cyclacel Pharmaceuticals's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyclacel Pharmaceuticals (FRA:UXI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (FRA:UXI) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

CYCCP.PFD:USA CYCC:USA UXI:Germany

Address

200 Connell Drive, Suite 1500, Berkeley Heights, NJ, USA, 07922

Website

https://www.cyclacel.com

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.

Cyclacel Pharmaceuticals (FRA:UXI) Headlines

No Headlines